Compound

Our portfolio boasts over 300 active patents covering world-changing innovations. We back the teams we believe are best able to deploy revolutionary technologies. We have board representation at over 80% of our portfolio companies. We're committed to working alongside our founders to commercialize scientific discovery. Our portfolio companies have collectively raised over two billion dollars. We invest across the life cycle of a company from pre-seed to pre-IPO. Our Name The name, Fine Structure Ventures®, is perhaps most meaningful to the scientist-entrepreneurs we partner with. In physics, the fine-structure constant, commonly denoted by α (the Greek letter alpha), is named for the spacing between the spectral lines in the fine structure of the hydrogen atom. It is a dimensionless, fundamental physical constant which describes the interaction between elementary charged particles, such as electrons, and an electromagnetic field. If the value of alpha were much different from the one we know, it would impact whether nuclear fusion within stars produces carbon or whether atoms can form stable molecules–both of which are critical for life. The fine structure constant is moreover the single best predicted constant in all of physics. Quantum electrodynamics, a field founded by Julian Schwinger, Richard Feynman, and Freeman Dyson, predict its value from first principles, and the associated experiments match to 11 digits. At Fine Structure Ventures, we are also making predictions to realize alpha, used in this context to represent excess return on investment. We take a first principles approach, looking for technologies that, if realized at scale, would have obvious, dramatic, global impact. While we only aspire to the brilliance of Dyson or Feynman, we nevertheless seek unprecedented accuracy in our evaluation of investment opportunities. A Rich Legacy Fine Structure Ventures is rooted in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion under management. For the last fifty years, our independent venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies, including Atari and MCI in the early days. A Focused Team of Specialists Although we are backed by a resourceful global platform, we are a small team passionate about the impact science can make and singularly focused on the success of the entrepreneurs we are privileged to work with. We bring together decades of experience in investments, operations, entrepreneurship, and in scientific research.

elev8.vc is a B2B focused VC Fund based in Singapore, with interests globally. We invest in and support early-stage deep tech founders (up to Series A), to scale their businesses globally.

Unreasonable inventors are combining cutting edge scientific discoveries with the world's biggest challenges to build the next generation of global companies. These are the companies we create and invest in at Main Sequence. We have over $500m under management from lean-in LPs who help our portfolio to prosper. We are investing in the difficult to build companies others struggle to support. Our co-founder is Australia's $1.3b annual budget science agency - CSIRO We invest from seed to Series B, starting our journey as early as possible, driving advantage into our portfolio. Our Advantage Deep tech inventors need more. We have custom built Main Sequence to be ready to help you solve some of the world's greatest challenges with science. We are hands-on and have built a services offering to support founders alongside our capital. Our story Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science. CSIRO Innovation Funds 1 and 2 managed by Main Sequence, have invested in 39 companies since establishment in 2017. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The $240 million first CSIRO Innovation Fund , built on a cornerstone investment by government and CSIRO has completed its portfolio and invested in 27 companies since establishment in 2017. The second $300 million CSIRO Innovation Fund commenced investing mid-2021 and had already invested in 12 companies by the end of 2021. Following the Government’s announcement on 1 February 2022 of a reform agenda to accelerate commercialisation of research and collaboration with industry, including $150m support for CSIRO investment in future CSIRO Innovation Funds, Main Sequence welcomes the opportunity to continue to work closely with universities to commercialise Australian research and build Australian companies addressing global challenges. Each of our portfolio companies has some advantage delivered by either one of Australia's 43 universities or an industrial research organisation such as CSIRO. In some cases this exists before we invest, in others we facilitate it as part of the companies pathway to scale and impact.

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

It's our mission to accelerate a Tough Tech company's journey from ideation to commercialization by providing access to a unique combination of investment, infrastructure, and community. Long-term Capital The Engine Fund provides long-term capital to meet the unique needs of Tough Tech companies solving the world’s most urgent challenges. Labs, Equipment, Tools & Space The Engine Infrastructure provides access to specialized equipment and labs, both on-site and through a network of partner facilities, giving portfolio companies the tools and space necessary to work efficiently and economically. Connections The Engine Network facilitates the creation of long-term mutually beneficial relationships between founders, startups, corporates, government, strategic partners, and others.

We invest in opportunities backed by deep science. Xora is an early-stage investment platform of Temasek. We typically invest as a lead or co-lead investor in the Seed and Series A rounds, and later rounds (via our parent company). While we are not limited by geography, we prioritize opportunities that possess a strong linkage with the Singapore science & technology ecosystem. Leveraging the Temasek global network of investors and operating companies, we are active partners to ambitious founders building the next generation of impactful, world-changing companies. Our Team Our team possesses strong technical domain expertise in both physical and life sciences, and the intersection thereof, and are steeped in the nuances of early-stage deep science investing and venture building. We are global citizens with business experience in major markets. Our principles guide our engagement process and our investment decisions.We start with the people on the journey and a shared vision of the future. ​ We look for dogged persistence, unbounded creativity, acute self-awareness, a sense of urgency, and a passion for impact. We embrace both the technical and people complexity of science-based opportunities. ​ We welcome early and frequent contact and appreciate the opportunity to inform an emerging narrative. ​ We prefer brainstorming to pitches, and relationships to transactions. ​ We commit more than capital; we pledge our mindshare and our network.